Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SpyBiotech","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spy Biotech and Serum Institute of India Announce Dosed First Subjects in \nPhase I\/II Trial of a Novel Virus-Like Particle Vaccine Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"3P Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Braavos Investment Advisers","pharmaFlowCategory":"D","amount":"$32.5 million","upfrontCash":"Undisclosed","newsHeadline":"SpyBiotech Raises $32.5M in Series A Funding and Appoints Lutz B. Giebel as Chairman","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by SpyBiotech

    Menu

    SpyBiotech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              SpyBiotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01

              Details:

              SpyBiotech's primary program, SPYVLP01, a candidate vaccine, is presently undergoing Phase I clinical trial evaluation with patients for the treatment of human cytomegalovirus infection.

              Lead Product(s): SPYVLP01

              Therapeutic Area: Infections and Infectious Diseases Product Name: SPYVLP01

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SpyBiotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01

              Details:

              SPYVLP01, a vaccine targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology. There is currently no approved vaccine against HCMV.

              Lead Product(s): SPYVLP01

              Therapeutic Area: Infections and Infectious Diseases Product Name: SPYVLP01

              Highest Development Status: IND Enabling Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SpyBiotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemi...

              Details:

              The funding will support the development of next generation pan-SARS-CoV-2 and pan-sarbecovirus vaccines using novel SpyVector platform. SpyVector is a platform based on recombinant adenovirus.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Vaccine

              Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

              Deal Size: $4.0 million Upfront Cash: Undisclosed

              Deal Type: Funding March 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SpyBiotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SpyBiotech Raises $32.5M in Series A Funding and Appoints Lutz B. Giebel as Chairman

              Details:

              Proceeds will advance the clinical development of SpyBiotech’s novel vaccine technology platform, based on its proprietary SpyCatcher/SpyTag protein “superglue” technology.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Braavos Investment Advisers

              Deal Size: $32.5 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing February 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SpyBiotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement

              Details:

              SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.

              Lead Product(s): VLPs based vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Recipient: 3P Biopharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SpyBiotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Spy Biotech and Serum Institute of India Announce Dosed First Subjects in Phase I/II Trial of a Novel Virus-Like Particle Vaccine Targeting COVID-19

              Details:

              SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. The Phase I/II study has been initiated in Australia.

              Lead Product(s): Virus-like-particle vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Serum Institute of India

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY